Peter R Rossing

List of Publications by Citations

566 papers	27,743 citations	82 h-index	147 g-index
633 ext. papers	36,676 ext. citations	7.6 avg, IF	7.18 L-index

#	Paper	IF	Citations
566	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *European Heart Journal*, **2020**, 41, 255-323	9.5	1360
565	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, **2018**, 41, 2669-2701	14.6	1307
564	Dapagliflozin in Patients with Chronic Kidney Disease. *New England Journal of Medicine*, **2020**, 383, 1436-1446	59.2	865
563	Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. *Lancet, The*, **2012**, 380, 1662-73	40	664
562	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia*, **2018**, 61, 2461-2498	10.3	656
561	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, **2020**, 43, 487-493	14.6	483
560	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. *Kidney International*, **2011**, 79, 1331-40	9.9	468
559	Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, **2020**, 383, 2219-2229	59.2	347
558	Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2015**, 314, 884-94	27.4	342
557	Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. *BMJ: British Medical Journal*, **1996**, 313, 779-84		314
556	Diabetes and Hypertension: A Position Statement by the American Diabetes Association. *Diabetes Care*, **2017**, 40, 1273-1284	14.6	312
555	Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. *Lancet, The*, **2012**, 380, 1649-61	40	301
554	Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. *Diabetologia*, **1991**, 34, 655-61	10.3	293
553	Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. *Diabetes Care*, **2003**, 26, 1258-64	14.6	279
552	Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. *BMJ, The*, **2004**, 328, 1105	5.9	270
551	Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 ́years follow-up on the Steno-2 randomised trial. *Diabetologia*, **2016**, 59, 2298-2307	10.3	268
550	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney International*, **2020**, 98, S1-S115	9.9	251

549	Diabetic kidney disease. *Nature Reviews Disease Primers*, **2015**, 1, 15018	51.1	241
548	Recommendations for biomarker identification and qualification in clinical proteomics. *Science Translational Medicine*, **2010**, 2, 46ps42	17.5	237
547	Urinary proteomics in diabetes and CKD. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 1283-90	12.7	235
546	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia*, **2020**, 63, 221-228	10.3	235
545	A catalog of genetic loci associated with kidney function from analyses of a million individuals. *Nature Genetics*, **2019**, 51, 957-972	36.3	217
544	Progression of nephropathy in type 2 diabetic patients. *Kidney International*, **2004**, 66, 1596-605	9.9	217
543	Progression of diabetic nephropathy. *Kidney International*, **2001**, 59, 702-9	9.9	216
542	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. *Lancet, The*, **2019**, 393, 1937-1947	40	209
541	Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. *Kidney International*, **2000**, 57, 601-6	9.9	197
540	Urinary proteomics for early diagnosis in diabetic nephropathy. *Diabetes*, **2012**, 61, 3304-13	0.9	191
539	Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. *Diabetes Care*, **2002**, 25, 859-64	14.6	184
538	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 597-609	18.1	177
537	New susceptibility loci associated with kidney disease in type 1 diabetes. *PLoS Genetics*, **2012**, 8, e1002923	6	176
536	Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. *Diabetologia*, **2004**, 47, 1936-9	10.3	169
535	Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. *Diabetes Care*, **2011**, 34, 442-7	14.6	167
534	Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. *Diabetes*, **1995**, 44, 489-94	0.9	165
533	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 1999-2010	12.7	164
532	Beneficial impact of spironolactone in diabetic nephropathy. *Kidney International*, **2005**, 68, 2829-36	9.9	164

531	Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. *Diabetes*, **2009**, 58, 1668-71	0.9	163
530	Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. *Diabetologia*, **1994**, 37, 511-6	10.3	158
529	Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. *Kidney International*, **2006**, 70, 536-42	9.9	145
528	Implementation of proteomic biomarkers: making it work. *European Journal of Clinical Investigation*, **2012**, 42, 1027-36	4.6	131
527	Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. *Diabetes*, **1997**, 46, 1182-8	0.9	130
526	Prolonged QTc interval predicts mortality in patients with Type 1 diabetes mellitus. *Diabetic Medicine*, **2001**, 18, 199-205	3.5	129
525	Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. *Diabetes Care*, **1994**, 17, 1247-51	14.6	128
524	Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. *BMJ: British Medical Journal*, **1996**, 313, 591-4		128
523	Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. *Diabetes Care*, **2006**, 29, 334-9	14.6	125
522	New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. *New England Journal of Medicine*, **2021**, 385, 1737-1749	59.2	125
521	Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. *Diabetes Care*, **2009**, 32, 1873-9	14.6	124
520	Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. *Current Diabetes Reports*, **2006**, 6, 479-83	5.6	123
519	Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. *Current Diabetes Reports*, **2013**, 13, 550-9	5.6	120
518	Diagnosis of diabetic kidney disease: state of the art and future perspective. *Kidney International Supplements*, **2018**, 8, 2-7	6.3	117
517	A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. *Diabetologia*, **2013**, 56, 259-67	10.3	117
516	Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. *Diabetes*, **1993**, 42, 715-9	0.9	117
515	Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. *Kidney International*, **2017**, 91, 1300-1311	9.9	116
514	Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. *Kidney International*, **2008**, 74, 649-54	9.9	110

513	Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. *Diabetes Care*, **2016**, 39, 222-30	14.6	109
512	YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. *Diabetes Care*, **2009**, 32, 323-8	14.6	107
511	Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. *Nephrology Dialysis Transplantation*, **2020**, 35, 274-282	4.3	105
510	Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. *PLoS ONE*, **2010**, 5, e13421	3.7	104
509	Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. *New England Journal of Medicine*, **2021**, 385, 2252-2263	59.2	103
508	Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes. *Diabetologia*, **2013**, 56, 298-310	10.3	102
507	Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. *Kidney International*, **2008**, 73, 1419-25	9.9	102
506	Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. *Diabetes Care*, **2008**, 31, 747-52	14.6	102
505	Vitamin D levels and mortality in type 2 diabetes. *Diabetes Care*, **2010**, 33, 2238-43	14.6	101
504	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. *New England Journal of Medicine*, **2020**, 382, 2493-2503	59.2	100
503	Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 515-527	18.1	99
502	Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. *Journal of Hypertension*, **2010**, 28, 2316-22	1.9	99
501	Global Changes in Food Supply and the Obesity Epidemic. *Current Obesity Reports*, **2016**, 5, 449-455	8.4	98
500	Unchanged incidence of diabetic nephropathy in IDDM patients. *Diabetes*, **1995**, 44, 739-43	0.9	97
499	Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. *Diabetic Medicine*, **2014**, 31, 1138-47	3.5	94
498	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. *Nephrology Dialysis Transplantation*, **2014**, 29, 1563-70	4.3	94
497	Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. *Diabetes Care*, **2008**, 31, 1170-6	14.6	93
496	Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. *Diabetes*, **2010**, 59, 2027-32	0.9	92

495	Pregnancy and progression of diabetic nephropathy. *Diabetologia*, **2002**, 45, 36-41	10.3	92
494	Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. *BMJ Open*, **2016**, 6, e010310	3	92
493	Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. *Lancet Diabetes and Endocrinology,the*, **2021**, 9, 22-31	18.1	91
492	Development and validation of GFR-estimating equations using diabetes, transplant and weight. *Nephrology Dialysis Transplantation*, **2010**, 25, 449-57	4.3	90
491	Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. *Diabetes Care*, **2008**, 31, 1177-82	14.6	87
490	Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. *American Journal of Kidney Diseases*, **1993**, 22, 188-95	7.4	87
489	Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. *Diabetes Care*, **2010**, 33, 1320-4	14.6	85
488	Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten yearsPexperience. *American Journal of Kidney Diseases*, **1995**, 26, 99-107	7.4	85
487	Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. *Diabetic Medicine*, **2010**, 27, 1144-50	3.5	83
486	Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. *BMC Nephrology*, **2016**, 17, 127	2.7	83
485	Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 429-441	18.1	81
484	Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes. *Diabetes*, **2016**, 65, 216-27	0.9	81
483	Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. *Kidney International*, **2011**, 79, 1113-8	9.9	81
482	On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy. *Diabetes*, **1995**, 44, 783-9	0.9	80
481	Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. *Diabetologia*, **1995**, 38, 798-803	10.3	79
480	Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes. *Diabetes Care*, **2013**, 36, 715-21	14.6	78
479	Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. *Diabetologia*, **1992**, 35, 447-51	10.3	78
478	Vitamin D levels, microvascular complications, and mortality in type 1 diabetes. *Diabetes Care*, **2011** , 34, 1081-5	14.6	76

477	Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. *Circulation*, **2021**, 143, 540-552	16.7	76
476	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 301-312	18.1	75
475	Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. *Diabetes Care*, **2010**, 33, 1567-72	14.6	75
474	Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study. *Journal of Hypertension*, **2007**, 25, 2479-85	1.9	74
473	QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2000**, 60, 323-32	2	74
472	Low birth weight. A risk factor for development of diabetic nephropathy?. *Diabetes*, **1995**, 44, 1405-7	0.9	74
471	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. *Diabetes*, **2018**, 67, 1414-1427	0.9	71
470	Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. *Kidney International*, **1998**, 53, 1002-6	9.9	71
469	Progression of diabetic nephropathy in normotensive type 1 diabetic patients. *Kidney International*, **1999**, 71, S101-5	9.9	71
468	The Genetic Landscape of Renal Complications in Type 1 Diabetes. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 557-574	12.7	69
467	Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. *Diabetes Care*, **2005**, 28, 1988-94	14.6	68
466	Global longitudinal strain is not impaired in type 1 diabetes patients without albuminuria: the Thousand & 1 study. *JACC: Cardiovascular Imaging*, **2015**, 8, 400-410	8.4	67
465	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. *Journal of the American Society of Nephrology: JASN*, **2019**, 30, 2000-2016	12.7	66
464	Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2008**, 68, 731-8	2	66
463	Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. *Diabetes*, **2006**, 55, 3550-5	0.9	66
462	Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. *Kidney International*, **2001**, 60, 277-83	9.9	66
461	Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. *Kidney International*, **2020**, 98, 839-848	9.9	65
460	Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. *Diabetologia*, **2006**, 49, 11-9	10.3	65

459	Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. *Diabetes Care*, **1999**, 22, 478-83	14.6	65
458	Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy. *Diabetologia*, **1996**, 39, 1590-7	10.3	65
457	Trimethylamine N-oxide (TMAO) as a New Potential Therapeutic Target for Insulin Resistance and Cancer. *Current Pharmaceutical Design*, **2017**, 23, 3699-3712	3.3	64
456	Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test. *Nephrology Dialysis Transplantation*, **2014**, 29, 1195-203	4.3	64
455	Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. *PLoS ONE*, **2008**, 3, e3363	3.7	64
454	The Baltic Sea: Estimates of total fisheries removals 1950–2007. *Fisheries Research*, **2011**, 108, 356-363	2.3	63
453	ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 771-9	12.7	63
452	Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. *Diabetes Research and Clinical Practice*, **2012**, 97, 71-6	7.4	62
451	Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. *Diabetic Medicine*, **2012**, 29, e184-90	3.5	61
450	Telomere length predicts all-cause mortality in patients with type 1 diabetes. *Diabetologia*, **2010**, 53, 45-8	10.3	61
449	Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. *BMC Nephrology*, **2010**, 11, 29	2.7	61
448	Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 3186-91	5.6	60
447	The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. *Proteomics - Clinical Applications*, **2008**, 2, 997-1007	3.1	60
446	Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. *Kidney International*, **1995**, 47, 1726-31	9.9	60
445	A urinary proteome-based classifier for the early detection of decline in glomerular filtration. *Nephrology Dialysis Transplantation*, **2017**, 32, 1510-1516	4.3	60
444	Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study. *Diabetologia*, **2014**, 57, 672-80	10.3	59
443	The changing epidemiology of diabetic microangiopathy in type 1 diabetes. *Diabetologia*, **2005**, 48, 1439-44	10.3	59
442	Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy. *Diabetic Medicine*, **1999**, 16, 555-62	3.5	59

441	Microalbuminuria: a parameter that has changed diabetes care. *Diabetes Research and Clinical Practice*, **2015**, 107, 1-8	7.4	58
440	Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes. *Clinical Chemistry*, **2011**, 57, 1556-65	5.5	58
439	Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. *Diabetologia*, **2008**, 51, 2100-7	10.3	57
438	Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. *Diabetes Care*, **2000**, 23, 1725-30	14.6	57
437	Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. *Kidney International Reports*, **2017**, 2, 1066-1075	4.1	55
436	The effect of liraglutide on renal function: A randomized clinical trial. *Diabetes, Obesity and Metabolism*, **2017**, 19, 239-247	6.7	55
435	Tubular and glomerular injury in diabetes and the impact of ACE inhibition. *Diabetes Care*, **2009**, 32, 1684-8	14.6	54
434	Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy. *Diabetes*, **1996**, 45, 367-369	0.9	54
433	Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. *Diabetes*, **1997**, 46, 481-7	0.9	53
432	Remission of nephrotic-range albuminuria in type 1 diabetic patients. *Diabetes Care*, **2001**, 24, 1972-7	14.6	53
431	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. *Nephrology Dialysis Transplantation*, **2020**, 35, 1700-1711	4.3	52
430	Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. *Kidney International*, **2017**, 91, 982-988	9.9	51
429	Progressive Decline in Estimated Glomerular Filtration Rate in Patients With Diabetes After Moderate Loss in Kidney Function-Even Without Albuminuria. *Diabetes Care*, **2019**, 42, 1886-1894	14.6	51
428	Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. *Diabetes*, **1997**, 46, 1182-1188	0.9	51
427	Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. *Journal of Internal Medicine*, **2015**, 277, 362-371	10.8	50
426	Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors. *Diabetes Care*, **2014**, 37, 1660-7	14.6	50
425	Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. *Kidney International*, **2005**, 68, 1250-7	9.9	50
424	Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study. *European Journal of Endocrinology*, **2015**, 172, 11-20	6.5	49

423	Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. *Diabetic Medicine*, **2015**, 32, 343-52	3.5	49
422	Serum uric acid as a new player in the development of diabetic nephropathy. *Journal of Renal Nutrition*, **2011**, 21, 124-7	3	49
421	Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. *Diabetes Care*, **2010**, 33, 2304-9	14.6	49
420	Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. *Kidney International*, **2005**, 68, 1446-50	9.9	49
419	Short stature and diabetic nephropathy. *BMJ: British Medical Journal*, **1995**, 310, 296-7		49
418	initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial. *Diabetes Care*, **2011**, 34, 2078-83	14.6	48
417	Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?. *Diabetes Care*, **2003**, 26, 1501-6	14.6	48
416	Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. *Thrombosis Research*, **1996**, 81, 485-90	8.2	48
415	Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. *Diabetes*, **1995**, 44, 489-494	0.9	48
414	LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 870-878	18.1	48
413	Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. *Journal of Diabetes and Its Complications*, **2015**, 29, 670-4	3.2	47
412	Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 ́years of follow-up in the randomised Steno-2 study. *Diabetologia*, **2018**, 61, 1724-1733	10.3	47
411	Optimal dose of losartan for renoprotection in diabetic nephropathy. *Nephrology Dialysis Transplantation*, **2002**, 17, 1413-8	4.3	47
410	Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. *Kidney International*, **1996**, 49, 1778-82	9.9	47
409	Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. *Diabetes*, **1994**, 43, 1108-13	0.9	47
408	Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. *Nephrology Dialysis Transplantation*, **2017**, 32, 1866-1873	4.3	47
407	Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 1025-31	6.9	46
406	Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. *Seminars in Nephrology*, **2004**, 24, 147-57	4.8	46

405	The Danish Adult Diabetes Registry. *Clinical Epidemiology*, **2016**, 8, 429-434	5.9	46
404	Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study. *Diabetes*, **2017**, 66, 2278-2283	0.9	45
403	Improved prognosis of diabetic nephropathy in type 1 diabetes. *Kidney International*, **2015**, 87, 417-26	9.9	45
402	Cardiac (82)Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes. *Diabetologia*, **2016**, 59, 371-8	10.3	45
401	Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus. *Diabetic Medicine*, **1998**, 15, 900-19	3.5	44
400	Smoking and progression of diabetic nephropathy in type 1 diabetes. *Diabetes Care*, **2003**, 26, 911-6	14.6	44
399	Fish oil in diabetic nephropathy. *Diabetes Care*, **1996**, 19, 1214-9	14.6	44
398	Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. *PLoS ONE*, **2010**, 5, e13051	3.7	44
397	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. *Nephrology Dialysis Transplantation*, **2017**, 32, 2079-2089	4.3	44
396	Osteoprotegerin and mortality in type 2 diabetic patients. *Diabetes Care*, **2010**, 33, 2561-6	14.6	43
395	Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy. *Diabetologia*, **1993**, 36, 438-44	10.3	43
394	Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. *Diabetes Care*, **2019**, 42, 1512-1520	14.6	41
393	Need for better diabetes treatment for improved renal outcome. *Kidney International*, **2011**, S28-32	9.9	41
392	Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy. *Diabetes Care*, **2000**, 23, 30-3	14.6	41
391	Vitamin D levels and asymptomatic coronary artery disease in type 2 diabetic patients with elevated urinary albumin excretion rate. *Diabetes Care*, **2012**, 35, 168-72	14.6	40
390	Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy. *Kidney International*, **1996**, 50, 579-85	9.9	40
389	Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria. *Journal of Diabetes and Its Complications*, **2016**, 30, 248-55	3.2	39
388	The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. *Current Opinion in Nephrology and Hypertension*, **1994**, 3, 292-300	3.5	38

387	Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors. *Journal of Clinical Medicine*, **2019**, 8,	5.1	37
386	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. *Circulation*, **2021**, 143, 438-448	16.7	36
385	Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study. *Cardiovascular Diabetology*, **2017**, 16, 55	8.7	35
384	High YKL-40 levels predict mortality in patients with type 2 diabetes. *Diabetes Research and Clinical Practice*, **2012**, 96, 84-9	7.4	35
383	Left ventricular hypertrophy in non-insulin-dependent diabetic patients with and without diabetic nephropathy. *Diabetic Medicine*, **1997**, 14, 538-46	3.5	35
382	Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. *Diabetes*, **1993**, 42, 715-719	0.9	35
381	A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. *Kidney International*, **2021**, 100, 215-224	9.9	35
380	The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. *Diabetologia*, **2013**, 56, 1845-55	10.3	34
379	Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. *Kidney International*, **2005**, 67, 2325-9	9.9	34
378	Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes. *Diabetes Care*, **2017**, 40, 391-397	14.6	33
377	Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. *Diabetes Care*, **2019**, 42, 1088-1094	14.6	33
376	Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. *Diabetes, Obesity and Metabolism*, **2009**, 11, 966-77	6.7	33
375	Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy. *Proteome Science*, **2010**, 8, 4	2.6	33
374	The effect of the relationship between tissue-type plasminogen activator and plasminogen activator inhibitor type 1 on tissue-type plasminogen activator activity in insulin-dependent diabetes mellitus. *Fibrinolysis*, **1994**, 8, 22-24		33
373	Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.. *European Heart Journal*, **2021**,	9.5	33
372	Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review. *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System*, **2016**, 17,	3	33
371	Effects of 12 weeksPtreatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. *Diabetologia*, **2013**, 56, 22-30	10.3	32
370	The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. *British Journal of Clinical Pharmacology*, **2015**, 80, 678-86	3.8	32

369	Cardiovascular autonomic neuropathy and subclinical cardiovascular disease in normoalbuminuric type 1 diabetic patients. *Diabetes*, **2012**, 61, 1822-30	0.9	32
368	Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy. *Nephrology Dialysis Transplantation*, **1996**, 11, 1019-1023	4.3	32
367	Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. *Diabetes, Obesity and Metabolism*, **2017**, 19, 901-905	6.7	31
366	Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB. *Diabetes*, **2016**, 65, 239-54	0.9	31
365	Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes. *Cardiovascular Diabetology*, **2019**, 18, 114	8.7	30
364	Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria. *Diabetes Care*, **2018**, 41, 1493-1500	14.6	30
363	Arterial stiffness and endothelial dysfunction independently and synergistically predict cardiovascular and renal outcome in patients with type 1 diabetes. *Diabetic Medicine*, **2012**, 29, 990-4	3.5	30
362	Glomerular size- and charge selectivity in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. *Diabetologia*, **1994**, 37, 195-201	10.3	30
361	Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. *Nephrology Dialysis Transplantation*, **2015**, 30 Suppl 4, iv86-95	4.3	29
360	Methylglyoxal is associated with changes in kidney function among individuals with screen-detected Type 2 diabetes mellitus. *Diabetic Medicine*, **2016**, 33, 1625-1631	3.5	29
359	Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci. *Immunologic Research*, **2016**, 64, 55-63	4.3	29
358	Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. *Scandinavian Journal of Clinical and Laboratory Investigation*, **1997**, 57, 427-34	2	29
357	Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. *Kidney International*, **2000**, 57, S32-S37	9.9	29
356	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data. *Diabetes Care*, **2019**, 42, 1454-1463	14.6	28
355	SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes. *Diabetologia*, **2015**, 58, 543-8	10.3	28
354	Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics. *Diabetes and Vascular Disease Research*, **2016**, 13, 321-30	3.3	28
353	Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes. *Cardiovascular Diabetology*, **2015**, 14, 59	8.7	28
352	Proteomic biomarkers in diabetic nephropathy--reality or future promise?. *Nephrology Dialysis Transplantation*, **2010**, 25, 2843-5	4.3	28

351	Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes. *Diabetologia*, **2010**, 53, 2129-33	10.3	28
350	Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria. *Cardiovascular Diabetology*, **2017**, 16, 88	8.7	27
349	Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. *American Journal of Nephrology*, **2014**, 40, 572-81	4.6	27
348	Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study. *Diabetologia*, **2012**, 55, 2489-93	10.3	27
347	Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy. *Diabetes Care* , **1996**, 19, 441-5	14.6	27
346	Unchanged incidence of diabetic nephropathy in IDDM patients. *Diabetes*, **1995**, 44, 739-743	0.9	27
345	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 880-893	18.1	27
344	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. *American Journal of Kidney Diseases*, **2021** , 77, 94-109	7.4	27
343	Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial. *Diabetic Medicine*, **2015**, 32, 374-81	3.5	26
342	Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. *Diabetologia*, **2010**, 53, 1576-80	10.3	26
341	Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients. *Clinical Proteomics*, **2010**, 6, 105-114	5	26
340	Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy. *Scandinavian Journal of Clinical and Laboratory Investigation*, **1992**, 52, 513-21	2	26
339	Metformin and cardiorenal outcomes in diabetes: A reappraisal. *Diabetes, Obesity and Metabolism*, **2020**, 22, 904-915	6.7	26
338	Improved Time in Range Over 1 Year Is Associated With Reduced Albuminuria in Individuals With Sensor-Augmented Insulin Pump-Treated Type 1 Diabetes. *Diabetes Care*, **2020**, 43, 2882-2885	14.6	26
337	NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis. *Cardiovascular Diabetology*, **2011**, 10, 71	8.7	25
336	Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. *Platelets*, **2010**, 21, 525-32	3.6	25
335	Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. *European Heart Journal*, **2021**, 42, 1216-1227	9.5	25
334	Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. *Annals of Internal Medicine*, **2021**, 174, 385-394	8	25

333	Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial. *Diabetes, Obesity and Metabolism*, **2017**, 19, 509-516	6.7	24
332	Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives. *Nephrologie Et Therapeutique*, **2018**, 14 Suppl 1, S31-S37	0.6	24
331	Impact of type 2 diabetes and duration of type 2 diabetes on cardiac structure and function. *International Journal of Cardiology*, **2016**, 221, 114-21	3.2	24
330	Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes. *Scientific Reports*, **2019**, 9, 16398	4.9	24
329	Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate. *European Journal of Preventive Cardiology*, **2017**, 24, 1517-1524	3.9	24
328	Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. *Diabetologia*, **2009**, 52, 46-9	10.3	24
327	Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. *Kidney International*, **2004**, 66, 1180-6	9.9	24
326	Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?. *Kidney International*, **2002**, 62, 192-8	9.9	24
325	Improved visual function in IDDM patients with unchanged cumulative incidence of sight-threatening diabetic retinopathy. *Diabetes Care*, **1998**, 21, 2007-15	14.6	24
324	Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy. *Diabetes Care*, **2019**, 42, 93-101	14.6	24
323	Effect of large weight reductions on measured and estimated kidney function. *BMC Nephrology*, **2017**, 18, 52	2.7	23
322	Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes - An observational follow-up study. *PLoS ONE*, **2018**, 13, e0196634	3.7	23
321	Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted?. *Nature Reviews Nephrology*, **2013**, 9, 128-30	14.9	23
320	Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?. *Journal of Hypertension*, **2013**, 31, 1646-52	1.9	23
319	Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. *Platelets*, **2009**, 20, 513-9	3.6	23
318	On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy. *Diabetes*, **1995**, 44, 783-789	0.9	23
317	Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension. *Nephrology Dialysis Transplantation*, **2018**, 33, 296-303	4.3	22
316	IGFBP-4 Fragments as Markers of Cardiovascular Mortality in Type 1 Diabetes Patients With and Without Nephropathy. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 3032-40	5.6	22

315	Vitamin D status and 5-year changes in urine albumin creatinine ratio and parathyroid hormone in a general population. *Endocrine*, **2013**, 44, 473-80	4	22
314	24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes - a cross-sectional study. *Cardiovascular Diabetology*, **2013**, 12, 122	8.7	22
313	Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. *Nephrology Dialysis Transplantation*, **2011**, 26, 3242-9	4.3	22
312	Polymorphisms in the interleukin-1 gene cluster do not contribute to the genetic susceptibility of diabetic nephropathy in Caucasian patients with IDDM. *Diabetes*, **1997**, 46, 1075-6	0.9	22
311	Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1. *American Journal of Kidney Diseases*, **2001**, 38, 1376-80	7.4	22
310	Procoagulant activity and intimal dysfunction in IDDM. *Diabetologia*, **1995**, 38, 73-8	10.3	22
309	Monitoring kidney function in diabetic nephropathy. *Diabetologia*, **1994**, 37, 708-12	10.3	22
308	Red cell Na+/Li+ countertransport in non-insulin-dependent diabetics with diabetic nephropathy. *Kidney International*, **1991**, 39, 135-40	9.9	22
307	Stratification of type 2 diabetes based on routine clinical markers. *Diabetes Research and Clinical Practice*, **2018**, 141, 275-283	7.4	22
306	Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria. *Cardiovascular Diabetology*, **2018**, 17, 50	8.7	21
305	Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes. *Journal of Hypertension*, **2015**, 33, 2123-32	1.9	21
304	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. *BMJ Open Diabetes Research and Care*, **2014**, 2, e000011	4.5	21
303	Ambulatory tonometric blood pressure measurements in patients with diabetes. *Diabetes Technology and Therapeutics*, **2012**, 14, 453-6	8.1	21
302	Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. *Diabetes*, **1994**, 43, 1108-1113	0.9	21
301	Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2019**, 21, 2006-2011	6.7	20
300	Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. *Nephrology Dialysis Transplantation*, **2020**,	4.3	20
299	Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 925-933	18.1	20
298	Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes. *Diabetes Care*, **2019**, 42, 1112-1119	14.6	19

297	Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18 year follow-up study. *Diabetologia*, **2014**, 57, 2201-7	10.3	19
296	Common variant in the HMGA2 gene increases susceptibility to nephropathy in patients with type 2 diabetes. *Diabetologia*, **2013**, 56, 323-9	10.3	19
295	Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. *Amino Acids*, **2012**, 42, 1627-39	3.5	19
294	Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System*, **2012**, 13, 118-21	3	19
293	A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus. *Diabetologia*, **2010**, 53, 2562-8	10.3	19
292	Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. *Nephrology Dialysis Transplantation*, **2003**, 18, 293-7	4.3	19
291	Renal protection in diabetes: an emerging role for calcium antagonists. *Journal of Hypertension*, **1996**, 14, S21-5	1.9	19
290	Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. *Diabetes*, **1997**, 46, 481-487	0.9	19
289	Metabolomic Assessment Reveals Alteration in Polyols and Branched Chain Amino Acids Associated With Present and Future Renal Impairment in a Discovery Cohort of 637 Persons With Type 1 Diabetes. *Frontiers in Endocrinology*, **2019**, 10, 818	5.7	19
288	Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes. *Diabetic Medicine*, **2018**, 35, 1375-1382	3.5	19
287	Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: a longitudinal follow-up study. *Diabetic Medicine*, **2015**, 32, 1445-52	3.5	18
286	Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System*, **2013**, 14, 161-6	3	18
285	Urinary neutrophil gelatinase-associated lipocalin and progression of diabetic nephropathy in type 1 diabetic patients in a four-year follow-up study. *Nephron Clinical Practice*, **2011**, 118, c130-5		18
284	Finding diabetic nephropathy biomarkers in the plasma peptidome by high-throughput magnetic bead processing and MALDI-TOF-MS analysis. *Proteomics - Clinical Applications*, **2010**, 4, 697-705	3.1	18
283	Low birth weight. A risk factor for development of diabetic nephropathy?. *Diabetes*, **1995**, 44, 1405-1407	0.9	18
282	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. *Diabetes*, **2021**, 70, 1-16	0.9	18
281	Novel risk genes identified in a genome-wide association study for coronary artery disease in patients with type 1 diabetes. *Cardiovascular Diabetology*, **2018**, 17, 61	8.7	17
280	Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. *Proteomics*, **2013**, 13, 2967-75	4.8	17

279	Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. *Kidney International*, **2017**, 92, 1242-1248	9.9	17
278	Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction. *Journal of Diabetes Research*, **2015**, 2015, 539787	3.9	17
277	Central hemodynamics are associated with cardiovascular disease and albuminuria in type 1 diabetes. *American Journal of Hypertension*, **2014**, 27, 1152-9	2.3	17
276	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. *Journal of the American College of Cardiology*, **2021**, 78, 142-152	15.1	17
275	Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria. *Diabetologia*, **2016**, 59, 1549-1557	10.3	17
274	A novel rare CUBN variant and three additional genes identified in Europeans with and without diabetes: results from an exome-wide association study of albuminuria. *Diabetologia*, **2019**, 62, 292-305	10.3	17
273	Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies. *Cardiovascular Diabetology*, **2017**, 16, 139	8.7	16
272	Presence of micro- and macroalbuminuria and the association with cardiac mechanics in patients with type 2 diabetes. *European Heart Journal Cardiovascular Imaging*, **2018**, 19, 1034-1041	4.1	16
271	suPAR level is associated with myocardial impairment assessed with advanced echocardiography in patients with type 1 diabetes with normal ejection fraction and without known heart disease or end-stage renal disease. *European Journal of Endocrinology*, **2016**, 174, 745-53	6.5	16
270	Long-term prevention of diabetic nephropathy: an audit. *Diabetologia*, **2008**, 51, 956-61	10.3	16
269	Increased plasma apolipoprotein (a) levels in IDDM patients with diabetic nephropathy. *Diabetes Care*, **1996**, 19, 1382-7	14.6	16
268	Placebo-controlled comparison of captopril, metoprolol, and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension. *American Journal of Hypertension*, **1992**, 5, 257-65	2.3	16
267	Reduction in albuminuria predicts diminished progression in diabetic nephropathy. *Kidney International, Supplement*, **1994**, 45, S145-9		16
266	A New Panel-Estimated GFR, Including β-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse Population. *American Journal of Kidney Diseases*, **2021**, 77, 673-683.e1	7.4	16
265	Cardiac Autonomic Function Is Associated With the Coronary Microcirculatory Function in Patients With Type 2 Diabetes. *Diabetes*, **2016**, 65, 3129-38	0.9	16
264	Predictive value of echocardiography in Type 2 diabetes. *European Heart Journal Cardiovascular Imaging*, **2019**, 20, 687-693	4.1	16
263	Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes´and stage 4 chronic kidney disease. *Kidney International*, **2019**, 96, 1030-1036	9.9	15
262	Epicardial adipose tissue: an emerging biomarker of cardiovascular complications in type 2 diabetes?. *Therapeutic Advances in Endocrinology and Metabolism*, **2020**, 11, 2042018820928824	4.5	15

261	Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients. *Acta Diabetologica*, **2018**, 55, 1143-1150	3.9	15
260	Markers of Collagen Formation and Degradation Reflect Renal Function and Predict Adverse Outcomes in Patients With Type 1 Diabetes. *Diabetes Care*, **2019**, 42, 1760-1768	14.6	15
259	Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients. *Journal of Diabetes and Its Complications*, **2013**, 27, 59-63	3.2	15
258	Urinary adiponectin excretion rises with increasing albuminuria in type 1 diabetes. *Journal of Diabetes and Its Complications*, **2013**, 27, 604-8	3.2	15
257	Effect of Sensor-Augmented Pump Treatment Versus Multiple Daily Injections on Albuminuria: A 1-Year Randomized Study. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 4181-8	5.6	15
256	The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2012**, 72, 137-42	2	15
255	Birth weight--a risk factor for progression in diabetic nephropathy?. *Journal of Internal Medicine*, **2003**, 253, 343-50	10.8	15
254	Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathy. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2001**, 61, 349-56	2	15
253	Variability in response to albuminuria-lowering drugs: true or random?. *British Journal of Clinical Pharmacology*, **2017**, 83, 1197-1204	3.8	14
252	Association of Birth Weight With Type 2 Diabetes and Glycemic Traits: A Mendelian Randomization Study. *JAMA Network Open*, **2019**, 2, e1910915	10.4	14
251	Increased all-cause mortality in patients with type 1 diabetes and high-expression mannan-binding lectin genotypes: a 12-year follow-up study. *Diabetes Care*, **2015**, 38, 1898-903	14.6	14
250	A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) - Study Design and Baseline Characteristics. *Kidney and Blood Pressure Research*, **2018**, 43, 181-190	3.1	14
249	Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria. *Diabetologia*, **2017**, 60, 1883-1891	10.3	14
248	Uncarboxylated matrix Gla-protein: A biomarker of vitamin K status and cardiovascular risk. *Clinical Biochemistry*, **2020**, 83, 49-56	3.5	14
247	Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetes. *Cardiovascular Diabetology*, **2016**, 15, 137	8.7	14
246	Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker. *Acta Diabetologica*, **2021**, 58, 81-91	3.9	14
245	Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20´year life-course study in an inception cohort. *Diabetologia*, **2018**, 61, 231-241	10.3	14
244	Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy. *Diabetic Medicine*, **2012**, 29, 337-44	3.5	13

243	Omics-bioinformatics in the context of clinical data. *Methods in Molecular Biology*, **2011**, 719, 479-97	1.4	13
242	Renoprotection with and without blood pressure reduction. *Kidney International*, **2005**, S54-9	9.9	13
241	Natural course of kidney function in Type 2 diabetic patients with diabetic nephropathy. *Diabetic Medicine*, **1999**, 16, 388-94	3.5	13
240	Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus. *Journal of Translational Medicine*, **2016**, 14, 203	8.5	13
239	Urinary Proteomics and Precision Medicine for Chronic Kidney Disease: Current Status and Future Perspectives. *Proteomics - Clinical Applications*, **2019**, 13, e1800176	3.1	13
238	Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. *Journal of the American Society of Nephrology: JASN*, **2021**, 32, 2352-2361	12.7	13
237	Diabetic nephropathy in 2014: improved cardiorenal prognosis in diabetic nephropathy. *Nature Reviews Nephrology*, **2015**, 11, 68-70	14.9	12
236	Characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes. *Drug Design, Development and Therapy*, **2015**, 9, 3191-8	4.4	12
235	Urinary sulphate excretion and progression of diabetic nephropathy in Type 1 diabetes. *Diabetic Medicine*, **2013**, 30, 563-6	3.5	12
234	Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy. *Diabetes*, **1996**, 45, 367-369	0.9	12
233	Mitigating risk of aldosterone in diabetic kidney disease. *Current Opinion in Nephrology and Hypertension*, **2020**, 29, 145-151	3.5	12
232	Circulating Metabolites and Lipids Are Associated to Diabetic Retinopathy in Individuals With Type 1 Diabetes. *Diabetes*, **2020**, 69, 2217-2226	0.9	12
231	Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21´years of follow-up in the randomised Steno-2 Study. *Diabetologia*, **2019**, 62, 1575-1580	10.3	11
230	Genetic risk factors affecting mitochondrial function are associated with kidney disease in people with Type 1 diabetes. *Diabetic Medicine*, **2015**, 32, 1104-9	3.5	11
229	Early myocardial impairment in type 1 diabetes patients without known heart disease assessed with tissue Doppler echocardiography: The Thousand & 1 study. *Diabetes and Vascular Disease Research*, **2016**, 13, 260-7	3.3	11
228	NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients. *Cardiovascular Diabetology*, **2012**, 11, 19	8.7	11
227	Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients. *Cardiovascular Diabetology*, **2012**, 11, 119	8.7	11
226	Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.. *Kidney International Reports*, **2022**, 7, 36-45	4.1	11

225	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. *Diabetes Care*, **2021**, 44, 1894-1897	14.6	11
224	Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study. *Diabetologia*, **2021**, 64, 1982-1989	10.3	11
223	Generalised arterial calcification in normoalbuminuric patients with type 1 diabetes with and without cardiovascular autonomic neuropathy. *Diabetes and Vascular Disease Research*, **2019**, 16, 98-102	3.3	11
222	Plasma Metabolomics Identifies Markers of Impaired Renal Function: A Meta-analysis of 3089 Persons with Type 2 Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	11
221	Burden of Uncontrolled Metabolic Risk Factors and Left Ventricular Structure and Function in Patients With Type 2 Diabetes Mellitus. *Journal of the American Heart Association*, **2018**, 7, e008856	6	11
220	Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. *JACC: Heart Failure*, **2021**, 9, 807-820	7.9	11
219	Targeted Clinical Metabolite Profiling Platform for the Stratification of Diabetic Patients. *Metabolites*, **2019**, 9,	5.6	10
218	Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes. *Cardiovascular Diabetology*, **2020**, 19, 16	8.7	10
217	Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. *Journal of Diabetes and Its Complications*, **2017**, 31, 162-168	3.2	10
216	Tonometric devices for central aortic systolic pressure measurements in patients with type 1 diabetes: comparison of the BPro and SphygmoCor devices. *Blood Pressure Monitoring*, **2013**, 18, 156-60	1.3	10
215	Diabetes mellitus, hypertension and albuminuria in rural Zambia: a hospital-based survey. *Tropical Medicine and International Health*, **2013**, 18, 1080-1084	2.3	10
214	Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial. *Nephrology Dialysis Transplantation*, **2009**, 24, 3343-9	4.3	10
213	Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria. *Cardiovascular Diabetology*, **2011**, 10, 70	8.7	10
212	Pregnancy-associated plasma protein A in a large cohort of Type 1 diabetic patients with and without diabetic nephropathy-a prospective follow--up study. *Diabetic Medicine*, **2007**, 24, 1381-5	3.5	10
211	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial. *Circulation*, **2021**,	16.7	10
210	Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy. *Diabetes Care*, **1999**, 22, 491-4	14.6	10
209	Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. *Lancet Diabetes and Endocrinology,the*, **2021**, 9, 755-766	18.1	10
208	Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?. *Hypertension*, **2021**, 77, 1029-1035	8.5	10

207	Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers. *Diabetes, Obesity and Metabolism*, **2019**, 21, 720-725	6.7	10
206	Cardiac repolarization and depolarization in people with Type 1 diabetes with normal ejection fraction and without known heart disease: a case-control study. *Diabetic Medicine*, **2018**, 35, 1337-1344	3.5	10
205	Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). *Journal of Human Hypertension*, **2016**, 30, 46-52	2.6	9
204	Efficacy of Long-Term Remote Ischemic Conditioning on Vascular and Neuronal Function in Type 2 Diabetes Patients With Peripheral Arterial Disease. *Journal of the American Heart Association*, **2019**, 8, e011779	6	9
203	The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication. *Journal of Diabetes and Its Complications*, **2015**, 29, 1146-51	3.2	9
202	Associations between advanced glycation endproducts and matrix metalloproteinases and its inhibitor in individuals with type 1 diabetes. *Journal of Diabetes and Its Complications*, **2018**, 32, 325-329	3.2	9
201	Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 Study. *Diabetologia*, **2019**, 62, 2354-2364	10.2	9
200	Follow-up of intensive glucose control in type 2 diabetes. *New England Journal of Medicine*, **2009**, 360, 416; author reply 418	59.2	9
199	Renal protection in diabetes--an emerging role for calcium antagonists. *Cardiology*, **1997**, 88 Suppl 3, 56-62	1.6	9
198	Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. *Diabetes Care*, **2001**, 24, 177-80	14.6	9
197	Assessment of glomerular filtration rate in diabetic nephropathy using the plasma clearance of 51Cr-EDTA. *Scandinavian Journal of Clinical and Laboratory Investigation*, **1998**, 58, 405-13	2	9
196	Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. *Lancet Diabetes and Endocrinology,the*, **2021**, 9, 743-754	18.1	9
195	Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial. *EClinicalMedicine*, **2021** , 37, 100895	11.3	9
194	Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2019**, 21, 736-740	6.7	9
193	Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries. *Diabetes and Vascular Disease Research*, **2019**, 16, 47-56	3.3	9
192	Major adverse renal events (MARE): a proposal to unify renal endpoints. *Nephrology Dialysis Transplantation*, **2021**, 36, 491-497	4.3	9
191	Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. *Journal of Diabetes and Its Complications*, **2018**, 32, 1113-1117	3.2	9
190	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. *Kidney International*, **2021**,	9.9	9

189	Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. *Kidney International, Supplement*, **2000**, 75, S32-7		9
188	Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs?. *Nephrology Dialysis Transplantation*, **2015**, 30 Suppl 4, iv1-5	4.3	8
187	Increased plasma concentrations of midregional proatrial natriuretic Peptide is associated with risk of cardiorenal dysfunction in type 1 diabetes. *American Journal of Hypertension*, **2015**, 28, 772-9	2.3	8
186	Describing the fecal metabolome in cryogenically collected samples from healthy participants. *Scientific Reports*, **2020**, 10, 885	4.9	8
185	Statins are independently associated with increased HbA1c in type 1 diabetes--The Thousand & 1 Study. *Diabetes Research and Clinical Practice*, **2016**, 111, 51-7	7.4	8
184	Cardiovascular autonomic neuropathy and bone metabolism in Type 1 diabetes. *Diabetic Medicine*, **2018**, 35, 1596-1604	3.5	8
183	Sequential RAAS blockade: is it worth the risk?. *Advances in Chronic Kidney Disease*, **2014**, 21, 159-65	4.7	8
182	Treatment with continuous subcutaneous insulin infusion is associated with lower arterial stiffness. *Acta Diabetologica*, **2014**, 51, 955-62	3.9	8
181	Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy. *Diabetes Care*, **2011**, 34, 1192-8	14.6	8
180	Direct renin inhibition in chronic kidney disease. *British Journal of Clinical Pharmacology*, **2013**, 76, 580-6	3.8	8
179	Diabetes and risk of adverse events with calcium antagonists. *Diabetes Care*, **1998**, 21, 1779-80	14.6	8
178	Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria. *Diabetologia*, **2020**, 63, 2713-2724	10.3	8
177	Myocardial flow reserve assessed by cardiac 82Rb positron emission tomography/computed tomography is associated with albumin excretion in patients with Type 1 diabetes. *European Heart Journal Cardiovascular Imaging*, **2019**, 20, 796-803	4.1	8
176	Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria. *PLoS ONE*, **2021**, 16, e0244402	3.7	8
175	Effect of Liraglutide on Arterial Inflammation Assessed as [F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. *Circulation: Cardiovascular Imaging* , **2021**, 14, e012174	3.9	8
174	Effect of Pancreatic Hormones on pro-Atrial Natriuretic Peptide in Humans. *EBioMedicine*, **2017**, 17, 88-98	8.8	7
173	Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention. *Clinical Journal of the American Society of Nephrology: CJASN*, **2017**, 12, 1804-1813	6.9	7
172	Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1261-1265	6.7	7

171	Cardiac Autonomic Function Is Associated With Myocardial Flow Reserve in Type 1 Diabetes. *Diabetes*, **2019**, 68, 1277-1286	0.9	7
170	Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes. *Journal of Diabetes and Its Complications*, **2016**, 30, 1440-1442	3.2	7
169	Retinopathy is associated with impaired myocardial function assessed by advanced echocardiography in type 1 diabetes patients - The Thousand & 1 Study. *Diabetes Research and Clinical Practice*, **2016**, 116, 263-9	7.4	7
168	Impaired coronary microcirculation in type 2 diabetic patients is associated with elevated circulating regulatory T cells and reduced number of IL-21R+ T cells. *Cardiovascular Diabetology*, **2016**, 15, 67	8.7	7
167	The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes. *Journal of Negative Results in BioMedicine*, **2011**, 10, 4		7
166	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions. *PLoS ONE*, **2020**, 15, e0243737	3.7	7
165	Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. *Journal of Diabetes and Its Complications*, **2020**, 34, 107707	3.2	7
164	Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes. *Nephrology Dialysis Transplantation*, **2019**, 34, 659-666	4.3	7
163	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. *Diabetes Care*, **2021**, 44, 1020-1026	14.6	7
162	Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria - A double blind randomized placebo-controlled crossover trial. *Journal of Diabetes and Its Complications*, **2020**, 34, 107590	3.2	6
161	Serum uric acid and progression of diabetic nephropathy in type 1 diabetes. *Journal of Diabetes and Its Complications*, **2018**, 32, 470-473	3.2	6
160	Self-reported dyspnea is associated with impaired global longitudinal strain in ambulatory type 1 diabetes patients with normal ejection fraction and without known heart disease - The Thousand & 1 Study. *Journal of Diabetes and Its Complications*, **2016**, 30, 928-34	3.2	6
159	Pulse wave reflection is associated with diabetes duration, albuminuria and cardiovascular disease in type 1 diabetes. *Acta Diabetologica*, **2014**, 51, 973-80	3.9	6
158	Endothelial progenitor cells in long-standing asymptomatic type 1 diabetic patients with or without diabetic nephropathy. *Nephron Clinical Practice*, **2011**, 118, c309-14		6
157	Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2006**, 66, 173-80	2	6
156	Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy. *Clinical Science*, **1998**, 95, 709-17	6.5	6
155	Fibrinolysis in insulin-dependent diabetic patients with and without nephropathy. *Fibrinolysis*, **1996**, 10, 331-335		6
154	Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy. *Nephrology Dialysis Transplantation*, **1996**, 11, 1019-1023	4.3	6

153	Calcium antagonists and the diabetic hypertensive patient. *American Journal of Kidney Diseases*, **1993**, 21, 47-52	7.4	6
152	Cause-specific mortality according to urine albumin creatinine ratio in the general population. *PLoS ONE*, **2014**, 9, e93212	3.7	6
151	Identification of possible adverse drug reactions in clinical notes: The case of glucose-lowering medicines. *Journal of Research in Pharmacy Practice*, **2015**, 4, 64-72	1.3	6
150	Carotid-Femoral Pulse Wave Velocity as a Risk Marker for Development of Complications in Type 1 Diabetes Mellitus. *Journal of the American Heart Association*, **2020**, 9, e017165	6	6
149	Circulating Free Fatty Acid and Phospholipid Signature Predicts Early Rapid Kidney Function Decline in Patients With Type 1 Diabetes. *Diabetes Care*, **2021**, 44, 2098-2106	14.6	6
148	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. *Kidney International*, **2021**, 99, 926-939	9.9	6
147	Genome-wide association study of circulating interleukin 6 levels identifies novel loci. *Human Molecular Genetics*, **2021**, 30, 393-409	5.6	6
146	Prognostic value of ratio of transmitral early filling velocity to early diastolic strain rate in patients with Type 2 diabetes. *European Heart Journal Cardiovascular Imaging*, **2019**, 20, 1171-1178	4.1	5
145	High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes. *Journal of Diabetes and Its Complications*, **2016**, 30, 1603-1608	3.2	5
144	Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. *Nephrology Dialysis Transplantation*, **2011**, 26, 3573-7	4.3	5
143	Preventing diabetic nephropathy: an audit. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2001**, 61, 471-7	2	5
142	Linking Kidney and Cardiovascular Complications in Diabetes-Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture. *Diabetes*, **2021**, 70, 39-50	0.9	5
141	Linking glycemic dysregulation in diabetes to symptoms, comorbidities, and genetics through EHR data mining. *ELife*, **2019**, 8,	8.9	5
140	Concomitant diabetes with atrial fibrillation and anticoagulation management considerations. *European Heart Journal Supplements*, **2020**, 22, O78-O86	1.5	5
139	Performance of Indexed and Nonindexed Estimated GFR. *American Journal of Kidney Diseases*, **2020**, 76, 446-449	7.4	5
138	Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial. *Nephrology Dialysis Transplantation*, **2021**, 36, 2263-2273	4.3	5
137	Several Conventional Risk Markers Suggesting Presence of Albuminuria Are Weak Among Rural Africans With Hypertension. *Journal of Clinical Hypertension*, **2016**, 18, 27-30	2.3	5
136	Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial. *Diabetes, Obesity and Metabolism*, **2022**, 24, 125-134	6.7	5

135	A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. *Diabetes Care*, **2021**, 44, 901-907	14.6	5
134	Three-phase bone scintigraphy for diagnosis of Charcot neuropathic osteoarthropathy in the diabetic foot - does quantitative data improve diagnostic value?. *Clinical Physiology and Functional Imaging*, **2017**, 37, 30-36	2.4	4
133	Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?. *Journal of Nephrology*, **2020**, 33, 931-948	4.8	4
132	Post-Systolic Shortening by Speckle Tracking Echocardiography Predicts Cardiac Events in Type 2 Diabetes. *JACC: Cardiovascular Imaging*, **2020**, 13, 1289-1291	8.4	4
131	Arterial-ventricular coupling in type 1 diabetes: arterial stiffness is associated with impaired global longitudinal strain in type 1 diabetes patients-the Thousand & 1 Study. *Acta Diabetologica*, **2018**, 55, 21-29	3.9	4
130	Cardiac time intervals and the association with 2D-speckle-tracking, tissue Doppler and conventional echocardiography: the Thousand&1 Study. *International Journal of Cardiovascular Imaging*, **2016**, 32, 789-98	2.5	4
129	Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. *Journal of Diabetes and Its Complications*, **2017**, 31, 1164-1168	3.2	4
128	Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria. *Journal of Diabetes and Its Complications*, **2018**, 32, 1133-1140	3.2	4
127	Distinct Molecular Signatures of Clinical Clusters in People With Type 2 Diabetes: An IMI-RHAPSODY Study. *Diabetes*, **2021**, 70, 2683-2693	0.9	4
126	Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.. *Kidney International Supplements*, **2022**, 12, 27-35	6.3	4
125	Incident microalbuminuria and complement factor mannan-binding lectin-associated protein 19 in people with newly diagnosed type 1 diabetes. *Diabetes/Metabolism Research and Reviews*, **2017**, 33, e2895	7.5	3
124	A marker of type VI collagen formation (PRO-C6) is associated with higher arterial stiffness in type 1 diabetes. *Acta Diabetologica*, **2019**, 56, 711-712	3.9	3
123	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial. *Diabetes, Obesity and Metabolism*, **2020**, 22, 2077-2088	6.7	3
122	The effect of uric acid lowering treatment on albuminuria and renal function in Type 1 diabetes: a randomized clinical trial. *Diabetic Medicine*, **2018**, 35, 392-393	3.5	3
121	Type 1 diabetes is associated with T-wave morphology changes. The Thousand & 1 Study. *Journal of Electrocardiology*, **2018**, 51, S72-S77	1.4	3
120	Urinary alpha- and pi-glutathione s-transferases in adult patients with type 1 diabetes. *Nephron Extra*, **2014**, 4, 127-33		3
119	Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy. *Nephrology Dialysis Transplantation*, **2006**, 21, 2030-1	4.3	3
118	Renoprotective effects of renin-angiotensin-system inhibitors. *Lancet, The*, **2006**, 367, 898-9; author reply 900-2	40	3

117	Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.. *Diabetes Care*, **2022**,	14.6	3
116	Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: a Pooled Analysis of SUSTAIN 6 and LEADER Trials.. *Circulation*, **2021**,	16.7	3
115	Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. *Journal of the American Society of Nephrology: JASN*, **2021**,	12.7	3
114	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). *BMJ Open*, **2019**, 9, e029098	3	3
113	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. *Lancet Diabetes and Endocrinology,the* , **2021**,	18.1	3
112	Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial.. *Frontiers in Endocrinology*, **2021**, 12, 790405	5.7	3
111	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post-hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. *Nephrology Dialysis Transplantation*, **2021**,	4.3	3
110	Cardiovascular autonomic neuropathy and the impact on progression of diabetic kidney disease in type 1 diabetes. *BMJ Open Diabetes Research and Care*, **2021**, 9,	4.5	3
109	A Targeted Multiomics Approach to Identify Biomarkers Associated with Rapid eGFR Decline in Type 1 Diabetes. *American Journal of Nephrology*, **2020**, 51, 839-848	4.6	3
108	Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: The REMOVAL trial. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1371-1378	6.7	3
107	The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. *Scientific Reports*, **2021**, 11, 10624	4.9	3
106	Clinical Features and Natural Course of Diabetic Nephropathy **2019**, 21-32		3
105	Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial. *Journal of the American Heart Association*, **2021**, 10, e020418	6	3
104	Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. *BMJ Open Diabetes Research and Care*, **2021**, 9,	4.5	3
103	Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes. *Diabetes Care*, **2017**, 40, e32-e33	14.6	2
102	Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group. *American Journal of Hypertension*, **2019**, 32, 1146-1153	2.3	2
101	An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes. *International Journal of Cardiology*, **2019**, 289, 119-124	3.2	2
100	Mendelian randomization analysis does not support causal associations of birth weight with hypertension risk and blood pressure in adulthood. *European Journal of Epidemiology*, **2020**, 35, 685-697	12.1	2

99	Lipoprotein(a)and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria. *Journal of Diabetes and Its Complications*, **2020**, 34, 107593	3.2	2
98	Subclassification of diabetes based on quantitative traits. *Nature Reviews Nephrology*, **2018**, 14, 355-356	14.9	2
97	The effect of needle tenotomy on hammer, mallet and claw toe deformities in patients with diabetes, a retrospective study. *Journal of Clinical and Translational Endocrinology*, **2019**, 18, 100208	2.4	2
96	Cuff inflations do not affect night-time blood pressure: comparison of 24 h ambulatory blood pressure measured by a cuff and a tonometric device in type 2 diabetes. *Blood Pressure Monitoring*, **2015**, 20, 369-72	1.3	2
95	Discrepancy between tonometric ambulatory and cuff-based office blood pressure measurements in patients with type 1 diabetes. *Journal of Clinical Hypertension*, **2012**, 14, 686-93	2.3	2
94	Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study. *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System*, **2012**, 13, 250-3	3	2
93	Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. *Diabetes Care*, **2006**, 29, 747-8; author reply 748-9	14.6	2
92	Metabolomic and Proteomic Techniques for Establishing Biomarkers and Improving Our Understanding of Pathophysiology in Diabetic Nephropathy. *Methods in Molecular Biology*, **2020**, 2067, 287-306	1.4	2
91	Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes. *Nephrology Dialysis Transplantation*, **2020**,	4.3	2
90	Left ventricular remodelling and cardiac chamber sizes in long-term, normoalbuminuric type 1 diabetes patients with and without cardiovascular autonomic neuropathy. *Journal of Diabetes and Its Complications*, **2019**, 33, 171-177	3.2	2
89	Genome-wide association study of diabetic kidney disease highlights biology involved in renal basement membrane collagen		2
88	Changes in diabetes distress among people with type 2 diabetes during a risk screening programme for diabetic kidney disease - Longitudinal observations of the PRIORITY study. *Journal of Diabetes and Its Complications*, **2020**, 34, 107467	3.2	2
87	MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction. *Cardiovascular Diabetology*, **2020**, 19, 180	8.7	2
86	Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes. *Scientific Reports*, **2020**, 10, 11561	4.9	2
85	Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation. *Transplant International*, **2021**, 34, 1341-1359	3	2
84	Genome-wide association study on coronary artery disease in type 1 diabetes suggests beta-defensin 127 as a risk locus. *Cardiovascular Research*, **2021**, 117, 600-612	9.9	2
83	Prognostic Value of Early Systolic Lengthening by Strain Imaging in Type 2 Diabetes. *Journal of the American Society of Echocardiography*, **2021**, 34, 127-135	5.8	2
82	Non-invasive assessment of temporal changes in myocardial microvascular function in persons with type 2 diabetes and healthy controls. *Diabetic Medicine*, **2021**, 38, e14517	3.5	2

81	Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 () with Reduced Progression to End Stage Kidney Disease in Type 1 Diabetes. *Journal of the American Society of Nephrology: JASN*, **2021**, 32, 2634-2651	12.7	2
80	Sodium-glucose cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: Review of the current evidence. *Nephrology*, **2021**, 26, 1007-1017	2.2	2
79	Effect of Liraglutide on Vascular Inflammation Evaluated by [Cu]DOTATATE. *Diagnostics*, **2021**, 11,	3.8	2
78	Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. *Europace*, **2021**, 23, 1873-1891	3.9	2
77	The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists.. *Kidney International Reports*, **2022**, 7, 436-443	4.1	2
76	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial) **2019**, 9, e029098		2
75	Cardiac ventricular sizes are reduced in patients with long-term, normoalbuminuric type 1 diabetes compared to the non-diabetic background population. *Diabetes and Vascular Disease Research*, **2019**, 16, 289-296	3.3	1
74	Hyperoxia improves autonomic function in individuals with long-duration type 1 diabetes and macroalbuminuria. *Diabetic Medicine*, **2020**, 37, 1561-1568	3.5	1
73	SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. *Nephrology Dialysis Transplantation*, **2019**, 34,	4.3	1
72	FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) – A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. *Nephrology Dialysis Transplantation*, **2019**, 34,	4.3	1
71	Can ADAMTS13 lead us to the paradise of personalized medicine?. *Diabetes*, **2013**, 62, 3331-2	0.9	1
70	Experimental testing of skin reactions to insulin detemir in diabetes patients naïve to insulin detemir. *Skin Research and Technology*, **2011**, 17, 411-9	1.9	1
69	Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions.. *Kidney International Reports*, **2022**, 7, 699-707	4.1	1
68	Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes: the Thousand & 1 Study. *European Journal of Endocrinology*, **2020**, 182, 481-488	6.5	1
67	Quetelet (Body Mass) Index and Effects of Dapagliflozin in CKD.. *Diabetes, Obesity and Metabolism*, **2022**,	6.7	1
66	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. *International Journal of Cardiovascular Imaging*, **2021**, 1	2.5	1
65	40-LB: Association between Complement and Severe Retinal Complications in Type 1 Diabetes—An 18-Year Follow-Up Study. *Diabetes*, **2019**, 68, 40-LB	0.9	1
64	28-LB: Improved Time in Glucose Range over One Year Is Associated with Reduced Albuminuria in Sensor-Augmented Insulin Pump–Treated Type 1 Diabetes. *Diabetes*, **2020**, 69, 28-LB	0.9	1

63	Replication and cross-validation of T2D subtypes based on clinical variables: an IMI-RHAPSODY study		1
62	Sex differences in the association between myocardial function and prognosis in type 1 diabetes without known heart disease: the Thousand & 1 Study. *European Heart Journal Cardiovascular Imaging*, **2021**, 22, 1017-1025	4.1	1
61	A narrative review of new treatment options for chronic kidney disease in type 2 diabetes. *Annals of Translational Medicine*, **2021**, 9, 716	3.2	1
60	Biomarkers for early detection of kidney disease: a call for pathophysiological relevance. *Kidney International*, **2021**, 99, 1240-1241	9.9	1
59	Response to Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901-907. *Diabetes Care*, **2021**, 44, e140-e141	14.6	1
58	Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes. *PLoS ONE*, **2021**, 16, e0254859	3.7	1
57	Successful glucose lowering therapy triumphs in heart failure. *EClinicalMedicine*, **2021**, 37, 100996	11.3	1
56	Urinary peptidome and diabetic retinopathy in the DIRECT-Protect 1 and 2 trials. *Diabetic Medicine*, **2021**, 38, e14634	3.5	1
55	Response to Comment on Pilemann-Lyberg et al. Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. Diabetes Care 2019;42:1088-1094. *Diabetes Care*, **2019**, 42, e188	14.6	1
54	Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes. *Diabetic Medicine*, **2021**, 38, e14459	3.5	1
53	Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. *Diabetes Care*, **2021**, 44, 595-603	14.6	1
52	Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial. *Diabetes, Obesity and Metabolism*, **2021**, 23, 2651-2659	6.7	1
51	Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. *Journal of the American Society of Nephrology: JASN*, **2021**, 32, 2900-2911	12.7	1
50	Effect of liraglutide on expression of inflammatory genes in type 2 diabetes. *Scientific Reports*, **2021**, 11, 18522	4.9	1
49	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.. *Cardiovascular Diabetology*, **2022**, 21, 50	8.7	1
48	Microalbuminuria constitutes a Clinical Action Item for Clinicians in 2021.. *American Journal of Medicine*, **2021**,	2.4	1
47	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.. *Diabetologia*, **2022**, 1	10.3	1
46	Precision diagnostic approach to predict 5-year risk for microvascular complications in type 1 diabetes.. *EBioMedicine*, **2022**, 80, 104032	8.8	1

45	Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals. *Communications Biology*, **2022**, 5,	6.7	1
44	Improvements in albuminuria and chronic kidney disease progression with the appetite suppressant lorcaserin. *Kidney International*, **2019**, 95, 1287-1288	9.9	0
43	Is renal Na+,K+-ATPase a new target for renin-angiotensin blocking agents in diabetic nephropathy?. *Journal of Physiology*, **2008**, 586, 5283	3.9	0
42	Association between severe diabetic retinopathy and lectin pathway proteins - an 18-year follow-up study with newly diagnosed type 1 diabetes patients. *Immunobiology*, **2020**, 225, 151939	3.4	0
41	Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study. *Diabetic Medicine*, **2021**, 38, e14405	3.5	0
40	A primer on metabolic memory: why existing diabesity treatments fail. *CKJ: Clinical Kidney Journal*, **2021**, 14, 756-767	4.5	0
39	Relationship between peripheral neuropathy, diastolic function and adverse cardiovascular outcome in individuals with type 1 diabetes mellitus without known cardiovascular disease: Results from the Thousand & 1 Study. *Diabetes, Obesity and Metabolism*, **2021**, 23, 158-165	6.7	0
38	The Low-Expression Variant of Is Associated With Cardiovascular Disease in Type 1 Diabetes. *Diabetes*, **2021**, 70, 2391-2401	0.9	0
37	Faecal biomarkers in type 1 diabetes´with and without´diabetic nephropathy. *Scientific Reports*, **2021**, 11, 15208	4.9	0
36	The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls.. *Frontiers in Endocrinology*, **2021**, 12, 780679	5.7	0
35	Cardiovascular Autonomic Neuropathy in Type 1 Diabetes Is Associated With Disturbances in TCA, Lipid, and Glucose Metabolism.. *Frontiers in Endocrinology*, **2022**, 13, 831793	5.7	0
34	Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor.. *Frontiers in Pharmacology*, **2022**, 13, 799915	5.6	0
33	[OP.4B.04] URINARY PROTEOMICS PREDICTS MORTALITY IN TYPE 2 DIABETES PATIENTS WITH MICROALBUMINURIA. *Journal of Hypertension*, **2017**, 35, e38-e39	1.9	
32	PP.33.31. *Journal of Hypertension*, **2015**, 33, e437	1.9	
31	PP.33.30. *Journal of Hypertension*, **2015**, 33, e436-e437	1.9	
30	RNA oxidation and albuminuria in type 1 diabetes patients. *Cardiovascular Endocrinology*, **2013**, 2, 103-105		
29	Role of Plasma Homocysteine and Plasminogen Activator Inhibitor-1 in the Progression of Diabetic Nephropathy **2002**, 97-101		
28	Concentration changes during venous occlusion of proteins with affinity for extracellular matrix in insulin-dependent diabetes mellitus a sign of vascular damage in patients with diabetic nephropathy?. *Fibrinolysis and Proteolysis*, **1999**, 13, 142-147		

27	Prevention and treatment of diabetic nephropathy with blood pressure lowering drugs. *Nephrology* , **1996**, 2, s45-s48	2.2
26	What Have We Learned so Far From the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Clinical Practice?. *Advances in Chronic Kidney Disease*, **2021**, 28, 290-297	4.7
25	The authors reply.. *Kidney International*, **2021**,	9.9
24	Serum Creatinine and Other Measures of GFR in Diabetes **2000**, 95-101	
23	How Does Risk Screening for Kidney Disease Influence Diabetes Distress?. *Diabetes*, **2018**, 67, 819-P	0.9
22	237-OR: Beneficial Impact of Intensified Multifactorial Intervention on Stroke□he Steno-2 Study. *Diabetes*, **2019**, 68, 237-OR	0.9
21	456-P: The REMOVAL Trial: Effect of Metformin on Markers of Cardiometabolic Risk in Patients with Type 1 Diabetes. *Diabetes*, **2019**, 68, 456-P	0.9
20	526-P: Dapagliflozin Improves the Urinary CKD273 Proteomic Score When Added to Renin-Angiotensin Blockade in Patients with Type 2 Diabetes and Nephropathy. *Diabetes*, **2019**, 68, 526-P	0.9
19	490-P: Renal Effects of Metformin in Type 1 Diabetes (T1D): The REMOVAL Trial. *Diabetes*, **2020**, 69, 490-P	0.9
18	1532-P: Investigating Biomarkers of the Immune Response and Tissue Remodeling in Patients with Type 2 Diabetes with Microalbuminuria. *Diabetes*, **2020**, 69, 1532-P	0.9
17	Serum Creatinine and other Measures of GFR in Diabetes **1998**, 97-102	
16	Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes. *Journal of Diabetes*, **2021**, 13, 754-763	3.8
15	OBESITY REMAINS A MAJOR RISK FACTOR ASSOCIATED WITH VASCULAR STIFFENING IN TYPE 2 DIABETES. *Journal of Hypertension*, **2019**, 37, e65	1.9
14	SP417EFFECT OF DAPAGLIFLOZIN ON ALBUMINURIA AND THE RENIN-ANGIOTENSIN SYSTEM WHEN ADDED TO RENIN-ANGIOTENSIN BLOCKADE IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY. *Nephrology Dialysis Transplantation*, **2018**, 33, i488-i488	4.3
13	SP420ALTERED LEVELS OF PLASMA LIPIDS ARE ASSOCIATED WITH DIABETIC KIDNEY DISEASE: A CROSS-SECTIONAL STUDY OF PLASMA LIPIDOMICS IN TYPE 1 DIABETES. *Nephrology Dialysis Transplantation*, **2018**, 33, i489-i489	4.3
12	A3993 Myocardial flow reserve assessed by Cardiac 82Rb PET/CT is associated with albumin excretion in patients with type 1 diabetes. *Journal of Hypertension*, **2018**, 36, e147	1.9
11	SEX-SPECIFIC REGULATION OF URINARY PEPTIDES IN EARLY DIABETIC NEPHROPTHY. *Journal of Hypertension*, **2018**, 36, e240	1.9
10	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions **2020**, 15, e0243737	

9	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions **2020**, 15, e0243737	
8	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions **2020**, 15, e0243737	
7	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions **2020**, 15, e0243737	
6	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions **2020**, 15, e0243737	
5	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions **2020**, 15, e0243737	
4	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions **2020**, 15, e0243737	
3	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions **2020**, 15, e0243737	
2	Monitoring kidney function in diabetic nephropathy. *Diabetologia*, **1994**, 37, 708-712	10.3
1	Diabetic Kidney Disease: Identification, Prevention, and Treatment **2022**, 149-169	